Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) traded at $3.72 at close of the session on Monday, May 03, made an upward move of 0.54% on its previous day’s price.
Looking at the stock we see that its previous close was $3.7 and the beta (5Y monthly) reads 1.5 with the day’s price range being $3.6200 – 3.7800. The company has a trailing 12-month PE ratio of 0. In terms of its 52-week price range, RIGL has a high of $5.5 and a low of $1.64. The company’s stock has gained about 8.77% over that past 30 days.
Rigel Pharmaceuticals, Inc. has a market cap of $629.39 Million and is expected to release its quarterly earnings report on May 05, 2021. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the RIGL stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $0, with the EPS growth for the year raised at -$0.02 for 2021 and -$0.2 for next year. These figures represent -0.89% and 9% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $31.05 Million, with a low of $17.4 Million and a high of $80.89 Million. The median projection represents growth adding up to -44.3% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $156.36 Million, or +44% up from figures reported last year.
On the other hand, looking at the outlook for the RIGL stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 6 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Rigel Pharmaceuticals, Inc. (RIGL) stock as a Hold, while 6 rate it as a Buy. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas none suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the RIGL stock currently stands at 0, and the current price level is 4.62% off its SMA20 and -2.47% from its 50-day simple moving average. The RSI (14) is pointing at 51.59 while the volatility over the past week is 4.69% and jumps to 5.69% over the past one month. The beta value is 1.5, while the average true range (ATR) is currently pointing at 0.21. The average price target for the stock over the next 12 months is $8.5, with the estimates having a low of $7 and a high of $11. These price ends are 88.17% and +195.7% off the current price level respectively, although investors could be excited at the prospect of a +115.05% if the RIGL share price touches on the median price of $8.
Let’s briefly compare Rigel Pharmaceuticals, Inc. (RIGL) stock to its peers. We find that current price change of +0.54% and +107.82% over the past 12 months for RIGL betters that of Zoetis Inc Cl A (ZTS), which has seen its stock price fall -0.85% in the last trading session and was +33.81% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has climbed 0.06% previous session, but was -6.91% down over the past year, while Catalent Inc (CTLT) was also up 0.54% in the last session, while its price remained in the green at 107.82% over the same period. Rigel Pharmaceuticals, Inc. has a P/E ratio of 0 compared to Zoetis Inc Cl A’s 50.55 and Takeda Pharmaceutical Co. Ltd’s 31.69. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at -0.72% and -0.54%, respectively, at close of the trading.
Coming back to Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), we note that the average 3-month trading volume was 3.85 Million, while that of the preceding 10-day period stands at 1.86 Million. Current shares outstanding are 170.12 Million.
According to data from Thomson Reuters, insiders hold 0.17% of the company’s shares while institutions hold 85.47%. The data shows that short shares as of April 14, 2021, stood at 23.34 Million at a short ratio of 6.97. This represents a 13.72% short interest in shares outstanding on April 14, 2021. Shares short rose in April from the previous month at 16.87 Million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock +6.29% up in year-to-date price movement.